Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab

DRUG2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Metastatic Colorectal Cancer

Phase 1

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

RecruitingNCT06202001

Cancer Institute and Hospital, Chinese Academy of Medical SciencesMetastatic Colorectal Cancer

Start: 2022-10-01End: 2026-09-30Target: 70Updated: 2024-04-02

Phase 2

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

Active, not recruitingNCT06403709

Cancer Institute and Hospital, Chinese Academy of Medical SciencesMetastatic Colorectal Cancer

Start: 2022-08-01End: 2026-08-01Updated: 2024-09-24

Related Papers

Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study

Signal Transduction and Targeted Therapy2026-04-09

Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second‐line therapy for patients with metastatic colorectal cancer.

Journal of Clinical Oncology2025-01-27